Three Orelabrutinib Studies Selected for Oral Sessions at Japanese Hematology Meeting
InnoCare Pharma said three studies of orelabrutinib were selected for oral presentation at the 88th Annual Meeting of the Japanese Society of Hematology.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.